• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HTX
Click for more information
0.00% 0.1¢

HEALTHLINX LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
HTXAppendix 3B21/09/11
HTXSigma Aldrich sign license agreement for IgY technologyPRICE SENSITIVE21/09/11
HTXChange of Director's Interest Notice19/09/11
HTXAppendix 3B19/09/11
HTXSection 708A Notice19/09/11
HTXAppendix 3B19/09/11
HTXCancellation of unquoted options09/09/11
HTXChina partner appointed for OvPlex diagnostic studyPRICE SENSITIVE09/09/11
HTXSection 708A Notice07/09/11
HTXAppendix 3B07/09/11
HTXBrandwood Biomedical appointed to manage TGA submission07/09/11
HTXShareholder Update06/09/11
HTXSection 708A Notice02/09/11
HTXAppendix 3B02/09/11
HTXAppendix 4E and Annual ReportPRICE SENSITIVE31/08/11
HTXSection 708A Notice30/08/11
HTXAppendix 3B30/08/11
HTXSection 708A Notice23/08/11
HTXAppendix 3B23/08/11
HTXAppendix 3Y X 322/08/11
HTXAppendix 3B for Share Purchase Plan Issue22/08/11
HTXSection 708A Notice22/08/11
HTXAppendix 3B22/08/11
HTXHealthLinx Share Purchase Closure18/08/11
HTXSection 708A Notice18/08/11
HTXAppendix 3B18/08/11
HTXSection 708A Notice04/08/11
HTXAppendix 3B04/08/11
HTXSection 708A Notice01/08/11
HTXAppendix 3B01/08/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/07/11
HTXAppendix 3B25/07/11
HTXSection 708A Cleansing Notice25/07/11
HTXChange of Director's Interest Notice21/07/11
HTXAppendix 3B21/07/11
HTXResults of Meeting19/07/11
HTXSection 708A Notice15/07/11
HTXAppendix 3B15/07/11
HTXSpringTree CLA terminated by mutual consent14/07/11
HTXHealthLinx Independent Valuation14/07/11
HTXSection 708A Notice12/07/11
HTXAppendix 3B12/07/11
HTXExtension of SPP closing date to 12 August 201105/07/11
HTXAppendix 3B30/06/11
HTXSection 708A Notice30/06/11
HTXHealthLinx secures additional equity fundingPRICE SENSITIVE30/06/11
HTXHealthLinx Share Purchase Plan22/06/11
HTXNotice of Extraordinary General Meeting/Proxy Form17/06/11
HTXShareholder Update17/06/11
HTXHealthLinx Limited Share Purchase PlanPRICE SENSITIVE15/06/11
HTXSales of OvPlex in Singapore exceed budgetPRICE SENSITIVE14/06/11
HTXSection 708A Notice09/06/11
HTXAppendix 3B09/06/11
HTXObjection to HealthLinx Patent DismissedPRICE SENSITIVE08/06/11
HTXOvPlex patent granted for AustraliaPRICE SENSITIVE03/06/11
HTXCollaboration with Garvan Institute on prostate cancerPRICE SENSITIVE17/05/11
HTXAGR2 Patent granted in EuropePRICE SENSITIVE10/05/11
HTXSection 708A Notice09/05/11
HTXAppendix 3B09/05/11
HTXUS based CPC appointed as CRO to manage FDA submission03/05/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/04/11
HTXResults of Meeting28/04/11
HTXExpiry of quoted options27/04/11
HTXSection 708A Cleansing Notice07/04/11
HTXAppendix 3B07/04/11
HTXShareholder Update31/03/11
HTXNotice of Extraordinary General Meeting/Proxy Form28/03/11
HTXO Six Media Group interviews Nick Gatsios with transcript16/03/11
HTXLarger OvPlex study confirms 93% diagnostic efficiencyPRICE SENSITIVE08/03/11
HTXSection 708A cleansing notice07/03/11
HTXAppendix 3B07/03/11
HTXAppendix 3B02/03/11
HTXAppendix 4d and half year Dec10 accountsPRICE SENSITIVE28/02/11
HTXKey OvPlex patent grantedPRICE SENSITIVE24/02/11
HTXOvarian cancer diagnostic study delivers exceptional resultsPRICE SENSITIVE15/02/11
HTXAppendix 3B03/02/11
HTXSection 708A Notice02/02/11
HTXAppendix 3B02/02/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/01/11
HTXResults of Meeting28/01/11
HTXAppendix 3B25/01/11
HTXCancellation of unquoted options05/01/11
HTXFinal Director's Interest Notice04/01/11
HTXSection 708A cleansing notice30/12/10
HTXAppendix 3B30/12/10
HTXNotice of Extraordinary General Meeting/Proxy Form24/12/10
HTXHealthLinx Board Change23/12/10
HTXDirectors and Officers Share Trading Policy17/12/10
HTXPart 1 of second study confirms superior efficacy of OvPlexPRICE SENSITIVE15/12/10
HTXHealthLinx signs commercial distribution deal in South KoreaPRICE SENSITIVE02/12/10
HTXInitial Director's Interest Notice01/12/10
HTXSection 708A cleansing notice30/11/10
HTXAppendix 3B30/11/10
HTXDr John Chiplin joins the Board of HealthLinx30/11/10
HTXExcellent early results in large OvPlex ovarian cancer studyPRICE SENSITIVE12/11/10
HTXNotice under section 708A29/10/10
HTXAppendix 3B29/10/10
HTXAppendix 4C - quarterly with commentaryPRICE SENSITIVE28/10/10
HTXResults of Meeting11/10/10
HTXManaging Directors Presentation to AGM11/10/10
HTXAppendix 3B
21/09/11
HTXSigma Aldrich sign license agreement for IgY technology
21/09/11PRICE SENSITIVE
HTXChange of Director's Interest Notice
19/09/11
HTXAppendix 3B
19/09/11
HTXSection 708A Notice
19/09/11
HTXAppendix 3B
19/09/11
HTXCancellation of unquoted options
09/09/11
HTXChina partner appointed for OvPlex diagnostic study
09/09/11PRICE SENSITIVE
HTXSection 708A Notice
07/09/11
HTXAppendix 3B
07/09/11
HTXBrandwood Biomedical appointed to manage TGA submission
07/09/11
HTXShareholder Update
06/09/11
HTXSection 708A Notice
02/09/11
HTXAppendix 3B
02/09/11
HTXAppendix 4E and Annual Report
31/08/11PRICE SENSITIVE
HTXSection 708A Notice
30/08/11
HTXAppendix 3B
30/08/11
HTXSection 708A Notice
23/08/11
HTXAppendix 3B
23/08/11
HTXAppendix 3Y X 3
22/08/11
HTXAppendix 3B for Share Purchase Plan Issue
22/08/11
HTXSection 708A Notice
22/08/11
HTXAppendix 3B
22/08/11
HTXHealthLinx Share Purchase Closure
18/08/11
HTXSection 708A Notice
18/08/11
HTXAppendix 3B
18/08/11
HTXSection 708A Notice
04/08/11
HTXAppendix 3B
04/08/11
HTXSection 708A Notice
01/08/11
HTXAppendix 3B
01/08/11
HTXAppendix 4C - quarterly
28/07/11PRICE SENSITIVE
HTXAppendix 3B
25/07/11
HTXSection 708A Cleansing Notice
25/07/11
HTXChange of Director's Interest Notice
21/07/11
HTXAppendix 3B
21/07/11
HTXResults of Meeting
19/07/11
HTXSection 708A Notice
15/07/11
HTXAppendix 3B
15/07/11
HTXSpringTree CLA terminated by mutual consent
14/07/11
HTXHealthLinx Independent Valuation
14/07/11
HTXSection 708A Notice
12/07/11
HTXAppendix 3B
12/07/11
HTXExtension of SPP closing date to 12 August 2011
05/07/11
HTXAppendix 3B
30/06/11
HTXSection 708A Notice
30/06/11
HTXHealthLinx secures additional equity funding
30/06/11PRICE SENSITIVE
HTXHealthLinx Share Purchase Plan
22/06/11
HTXNotice of Extraordinary General Meeting/Proxy Form
17/06/11
HTXShareholder Update
17/06/11
HTXHealthLinx Limited Share Purchase Plan
15/06/11PRICE SENSITIVE
HTXSales of OvPlex in Singapore exceed budget
14/06/11PRICE SENSITIVE
HTXSection 708A Notice
09/06/11
HTXAppendix 3B
09/06/11
HTXObjection to HealthLinx Patent Dismissed
08/06/11PRICE SENSITIVE
HTXOvPlex patent granted for Australia
03/06/11PRICE SENSITIVE
HTXCollaboration with Garvan Institute on prostate cancer
17/05/11PRICE SENSITIVE
HTXAGR2 Patent granted in Europe
10/05/11PRICE SENSITIVE
HTXSection 708A Notice
09/05/11
HTXAppendix 3B
09/05/11
HTXUS based CPC appointed as CRO to manage FDA submission
03/05/11
HTXAppendix 4C - quarterly
29/04/11PRICE SENSITIVE
HTXResults of Meeting
28/04/11
HTXExpiry of quoted options
27/04/11
HTXSection 708A Cleansing Notice
07/04/11
HTXAppendix 3B
07/04/11
HTXShareholder Update
31/03/11
HTXNotice of Extraordinary General Meeting/Proxy Form
28/03/11
HTXO Six Media Group interviews Nick Gatsios with transcript
16/03/11
HTXLarger OvPlex study confirms 93% diagnostic efficiency
08/03/11PRICE SENSITIVE
HTXSection 708A cleansing notice
07/03/11
HTXAppendix 3B
07/03/11
HTXAppendix 3B
02/03/11
HTXAppendix 4d and half year Dec10 accounts
28/02/11PRICE SENSITIVE
HTXKey OvPlex patent granted
24/02/11PRICE SENSITIVE
HTXOvarian cancer diagnostic study delivers exceptional results
15/02/11PRICE SENSITIVE
HTXAppendix 3B
03/02/11
HTXSection 708A Notice
02/02/11
HTXAppendix 3B
02/02/11
HTXAppendix 4C - quarterly
28/01/11PRICE SENSITIVE
HTXResults of Meeting
28/01/11
HTXAppendix 3B
25/01/11
HTXCancellation of unquoted options
05/01/11
HTXFinal Director's Interest Notice
04/01/11
HTXSection 708A cleansing notice
30/12/10
HTXAppendix 3B
30/12/10
HTXNotice of Extraordinary General Meeting/Proxy Form
24/12/10
HTXHealthLinx Board Change
23/12/10
HTXDirectors and Officers Share Trading Policy
17/12/10
HTXPart 1 of second study confirms superior efficacy of OvPlex
15/12/10PRICE SENSITIVE
HTXHealthLinx signs commercial distribution deal in South Korea
02/12/10PRICE SENSITIVE
HTXInitial Director's Interest Notice
01/12/10
HTXSection 708A cleansing notice
30/11/10
HTXAppendix 3B
30/11/10
HTXDr John Chiplin joins the Board of HealthLinx
30/11/10
HTXExcellent early results in large OvPlex ovarian cancer study
12/11/10PRICE SENSITIVE
HTXNotice under section 708A
29/10/10
HTXAppendix 3B
29/10/10
HTXAppendix 4C - quarterly with commentary
28/10/10PRICE SENSITIVE
HTXResults of Meeting
11/10/10
HTXManaging Directors Presentation to AGM
11/10/10
refresh Created with Sketch. REFRESH
 

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.